Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...

The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable (LAI) in schizophrenia (SOLARIS) has been completed, following the final visit of the last patient in the 48 weeks open ...

As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia." ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] ...

The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable (LAI) in schizophrenia (SOLARIS) has been completed, following the final visit of the last patient in the 48 weeks ...

As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.” The pivotal clinical phase 3 trial for the olanzapine ...

For someone living with schizophrenia, it can be especially difficult. That’s because schizophrenia affects the brain—both cognition and memory—making it more difficult to remember to adhere ...

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid ...

This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used ...

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.